Primary Immune Deficiency (PID) - Pipeline Review, H1 2020

Publication Month: Feb 2020 | No. of Pages: 125 Published By: Global Markets Direct
Single User License: US $ 2000
Corporate User License: US $ 6000

Primary Immune Deficiency (PID) - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2020, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 9, 3, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 9, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Introduction
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Primary Immune Deficiency (PID) - Therapeutics Assessment
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
Primary Immune Deficiency (PID) - Drug Profiles
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Discontinued Products
Primary Immune Deficiency (PID) - Product Development Milestones
Appendix

Tables and Figures

List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by AlloVir Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Emendo Biotherapeutics, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Enzyvant Sciences Ltd, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by GC Pharma, H1 2020
Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Grifols SA, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Rocket Pharmaceuticals Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2020
Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2020
Primary Immune Deficiency (PID) - Dormant Projects, H1 2020
Primary Immune Deficiency (PID) - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Primary Immune Deficiency (PID), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
ADMA Biologics Inc
AlloVir Inc
Biotest AG
Cellective BioTherapy Inc
Clinigen Group Plc
Emendo Biotherapeutics
Enzyvant Sciences Ltd
Evolve Biologics Inc
GC Pharma
GigaGen Inc
Grifols SA
Liminal BioSciences Inc
Mustang Bio Inc
Octapharma AG
Orchard Therapeutics Plc
Rocket Pharmaceuticals Inc
Sangamo Therapeutics Inc
Taiga Biotechnologies Inc
Takeda Pharmaceutical Co Ltd
X4 Pharmaceuticals Inc

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets